- Conditions
- Prostatic Neoplasms, Prostatic Cancer
- Interventions
- ETBX-071; adenoviral PSA vaccine, ETBX-061; adenoviral MUC1 vaccine, ETBX-051; adenoviral brachyury vaccine
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 405
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hematologic Neoplasms
- Interventions
- JNJ-95804306, AML SoC, CLL/SLL SoC
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 6
- States / cities
- Indianapolis, Indiana • Grand Rapids, Michigan • Piscataway, New Jersey + 3 more
- Conditions
- Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors, Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer
- Interventions
- BGB-B2033, Tislelizumab, Bevacizumab
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 630 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Duarte, California + 5 more
- Conditions
- Advanced Solid Malignancies
- Interventions
- CFI-402411, Pembrolizumab
- Drug
- Lead sponsor
- Treadwell Therapeutics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 9
- States / cities
- La Jolla, California • Los Angeles, California • New Haven, Connecticut + 6 more
- Conditions
- Cancer, Hematologic Malignancies, Leukemia, Myeloid Leukemia
- Interventions
- Arm 1- Dose Escalation, Arm 2- Dose Expansion
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 3
- States / cities
- Stony Brook, New York • Cleveland, Ohio • Houston, Texas
- Conditions
- Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor
- Interventions
- Visugromab RDE (recommended dose for expansion), Visugromab 6mg/kg, Nivolumab, Placebo Saline Infusion, Docetaxel
- Biological · Other · Drug
- Lead sponsor
- CatalYm GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Los Angeles, California • Mineola, New York + 2 more
- Conditions
- Metastatic Adenocarcinoma of the Colon or Rectum, Malignant Solid Tumors
- Interventions
- Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Sarasota, Florida • Houston, Texas + 1 more
- Conditions
- Advanced Solid Tumors
- Interventions
- mRNA-4359, Pembrolizumab, Ipilimumab, Nivolumab
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 361 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2032
- U.S. locations
- 16
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 11 more
- Conditions
- Neoplasms
- Interventions
- OMO-1
- Drug
- Lead sponsor
- Octimet Oncology N.V.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- KRAS p.G12C Mutant Advanced Solid Tumors
- Interventions
- sotorasib, Anti PD-1/L1, Midazolam
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 713 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 39
- States / cities
- Duarte, California • Los Angeles, California • San Francisco, California + 29 more
- Conditions
- Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma
- Interventions
- ALE.P02
- Drug
- Lead sponsor
- Alentis Therapeutics AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Fullerton, California • Los Angeles, California + 5 more
- Conditions
- EBV-Related Hodgkin Lymphoma, EBV-Related Lymphoproliferative Disorder, EBV Related Non-Hodgkin's Lymphoma
- Interventions
- Dose Level 1A: 2 x 10^7 cells/m2, Dose Level 2A: 6 x 10^7 cells/m2, Dose Level 2B: 6 x 10^7 cells/m2, Dose Level 3B: 2 x 10^8 cells/m2, Dose Level 3A: 2 x 10^8 cells/m2, Dose Level 1B: 2 x 10^7 cells/m2
- Biological
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Not listed
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2042
- U.S. locations
- 4
- States / cities
- Houston, Texas
- Conditions
- Solid Tumor, Adult
- Interventions
- FT538, Cyclophosphamide, Fludarabine, Monoclonal antibody - Dose Escalation, Monoclonal antibody - Dose Expansion
- Drug · Combination Product
- Lead sponsor
- Fate Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 4
- States / cities
- Hackensack, New Jersey • Nashville, Tennessee • Houston, Texas + 1 more
- Conditions
- Multiple Myeloma
- Interventions
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Daratumumab, Lenalidomide, Pomalidomide, Dexamethasone
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 24 more
- Conditions
- Solid Tumor, B-Raf Mutation-Related Tumors
- Interventions
- Brimarafenib
- Drug
- Lead sponsor
- MapKure, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 5
- States / cities
- Beverly Hills, California • Boston, Massachusetts • New York, New York + 2 more
- Conditions
- Solid Tumors Harboring NTRK Fusion
- Interventions
- Larotrectinib (Vitrakvi, BAY2757556)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- Up to 21 Years
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Palo Alto, California • Orlando, Florida + 7 more
- Conditions
- Non-small Cell Lung Cancer, Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB, Stage IV Non-small Cell Lung Cancer, EGFR Negative Non-Small Cell Lung Cancer
- Interventions
- Ceritinib, Docetaxel
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 2
- States / cities
- Orlando, Florida • Tampa, Florida
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia
- Interventions
- MRX-2843
- Drug
- Lead sponsor
- Meryx, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • New York, New York
- Conditions
- Acute Myelogenous Leukemia, Diffuse Large B-Cell Leukemia, Chronic Lymphocytic Leukemia, Follicular Lymphoma
- Interventions
- BMS-936564 (Anti-CXCR4)
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 7 more
- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- MDK-703, Checkpoint Inhibitor, Immune
- Drug
- Lead sponsor
- Medikine, Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 6
- States / cities
- Sarasota, Florida • Huntersville, North Carolina • Austin, Texas + 3 more
- Conditions
- Medical Oncology
- Interventions
- BAY1217389, Paclitaxel
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 6
- States / cities
- Santa Monica, California • Denver, Colorado • New Haven, Connecticut + 3 more
- Conditions
- Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
- Interventions
- ONC-392, Pembrolizumab, Docetaxel
- Drug
- Lead sponsor
- OncoC4, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 733 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 33
- States / cities
- Springdale, Arkansas • Davis, California • Downey, California + 27 more
- Conditions
- Cutaneous T Cell Lymphoma
- Interventions
- Ropeginterferon alfa-2b
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Breast Cancer
- Interventions
- Entinostat, Atezolizumab, Placebo
- Drug
- Lead sponsor
- Syndax Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Bakersfield, California • Fullerton, California + 15 more